Navigation Links
AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy
Date:11/18/2013

NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released the first phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients chronically infected with genotype 1 (GT1) hepatitis C virus (HCV). In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of AbbVie's 3D regimen achieved a sustained virologic response at 12 weeks post-treatment (SVR12) of 96 percent. The majority of patients were GT1a, considered the more difficult-to-treat subtype, and the SVR12 rates of GT1a and GT1b were 95 percent and 98 percent, respectively. The rate of virologic relapse or breakthrough was low, occurring in 1.7 percent of patients receiving the 3D regimen. In addition, discontinuation rates due to adverse events were low, and of an equal percentage (0.6 percent) in both active and placebo groups.

AbbVie's multinational HCV program is the largest all-oral, interferon-free clinical program in GT1 patients being conducted to date. GT1 (with subtypes 1a and 1b) is the most prevalent genotype worldwide, with a higher prevalence of 1a in the U.S. and 1b in Europe. SAPPHIRE-I is the first of six phase III trials supporting AbbVie's investigational 3D regimen for the treatment of GT1 hepatitis C patients.

"SAPPHIRE-I demonstrates that patients new to therapy with genotype 1 HCV achieved high rates of virologic response with AbbVie's interferon-free, all-oral 3D regimen plus ribavirin, and the SVR rate is consistent with results from our phase II studies," said Scott Brun, M.D., vice president, pharmaceutical development, AbbVie. "SAPPHIRE-I is the first of these studies to report results, and based on the progress of our clinical program to date, we are on track for major regulatory submissio
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AbbVie Named to S&P 500 Dividend Aristocrat Index
2. AbbVie Issues Inaugural Full-Year Outlook for 2013
3. AbbVie to Present at Barclays Global Health Care Conference
4. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
5. AbbVie to Host First-Quarter Earnings Conference Call
6. AbbVie Reports First-Quarter 2013 Financial Results
7. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
9. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
10. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
11. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 Cardiac Dimensions ... data from the TITAN II clinical trial of ... and sustained improvements in mitral regurgitation, functional improvement, ... long-term safety and efficacy data, which was consistent ... Sept. 13 at the 26 th annual ...
(Date:9/17/2014)... 17, 2014  Neuraltus Pharmaceuticals, Inc. announced today that ... program of NP001 for the treatment of amyotrophic lateral ... being highlighted today in an oral presentation at the ... being held in Bloomington, Minnesota , ... administration of a high dose of NP001 (2mg/kg) was ...
(Date:9/17/2014)... and MILL VALLEY, Calif. ... Sarcoma Alliance today announced a partnership in the ... will sponsor the Sarcoma Alliance Suzanne Renee Leider ... program offers financial assistance to reimburse sarcoma patients ... opinion from a sarcoma specialist. Scientific literature reinforces ...
Breaking Medicine Technology:Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3
... 31, 2011 Luminex Corporation (Nasdaq: LMNX ... Jefferies 2011 Global Healthcare Conference to be held June ... ) The investor presentation by Patrick ... at 9:00 a.m. Eastern time on Tuesday, June 7, 2011. ...
... 2011 The Procter & Gamble Company (NYSE: ... its U.S. Sustainability Expert Advisory Panel (SEAP). The new members ... Manager, Clinton Global Initiative Dr. Howard Frumkin – Dean, ... Terry Tamminen – Former Secretary, California Environmental Protection Agency ...
Cached Medicine Technology:Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference 2P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 2P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 3
(Date:9/18/2014)... Forty Fort, PA (PRWEB) September 18, 2014 ... remodeling display at the Bloomsburg Fair beginning this Saturday. ... The display is a great example of the products and ... three cabinet lines and various countertops for fair-goers to see. ... Home & Garden Show earlier this year and really is ...
(Date:9/18/2014)... 18, 2014 For many people, tomato soup ... online food delivery service provider, gives it a new stir—in ... Basil soup is a nod to this culinary classic—with a ... tangy tomato base, then Spoonful of Comfort's chefs stir in ... flashback to childhood has never tasted better. , Founder, ...
(Date:9/18/2014)... With the development of China’s ... adjusting human body physiology, preventing diseases, promoting health, ... a variety of specific populations. In 2013, the ... RMB187.4 billion, up 12.0% year on year, recording ... Full Report at http://www.marketresearchreports.biz/analysis/223449 , China's ...
(Date:9/18/2014)... Atlanta, GA (PRWEB) September 18, 2014 ... Counselor, recognizes that 1- sometimes, inner beauty has to ... strengths have to be acknowledged in order to be ... , Healing Hearts shows the world how to do ... Counseling and Life Coaching using the Healing Hearts system, ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 N-Zyme Scientifics ... successfully launching its first product a mere 8 months ... is a high performance glycan release enzyme used in ... research, and the basis for tissue pathology on Mass ... (Portsmouth, NH) for the North American market (PNGase F ...
Breaking Medicine News(10 mins):Health News:One Week Kitchens Taking Display to Bloomsburg Fair 2Health News:An Old Classic Brings New Soup Delivery Options to Spoonful of Comfort 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 3Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 4Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 3Health News:N-Zyme Scientifics Announces Successful Product Launch 2
... Neurologists at the University at Buffalo are beginning a ... the cause of multiple sclerosis (MS). The researchers will ... from narrowing of the primary veins outside the skull, ... CCSVI is a complex vascular condition discovered ...
... Study shows ways to optimize hand movements , FRIDAY, Oct. ... make it easier for people with multiple sclerosis to pick ... with MS use excessive force when lifting objects, which can ... from the University of Illinois at Chicago explained in a ...
... 29th October is "What can I do?". As the World ... symptoms and take action, learn to recognise the risk factors ... the European Society of Cardiology (ESC) emphasises that most of ... coronary heart disease - and thus the object of the ...
... to behavior dictated by society in which they live, researchers ... wide varieties of culture that differ from nation to nation, ... a new study suggests that chimpanzees have their own form ... found that chimpanzee populations that live next to each other ...
... relieves pain as well as seven-day regimen, researchers find , ... antibiotics may be as effective as a seven-day course in ... study has found. , The study appears in the October ... Neck Surgery . , Pain after a tonsillectomy can make ...
... and a possible death,toll into the millions, UC Davis ... diseases that move between,wildlife and people. The global ... of up to $75 million over five years and ... for International Development,(USAID) known in combination as the Emerging ...
Cached Medicine News:Health News:Buffalo neurologists investigate possible new underlying cause of MS 2Health News:Buffalo neurologists investigate possible new underlying cause of MS 3Health News:Buffalo neurologists investigate possible new underlying cause of MS 4Health News:Light Touch Helps Grip of MS Patients 2Health News:Learning the risks for stroke -- and taking action 2Health News:Learning the risks for stroke -- and taking action 3Health News:Chimps Show Signs of Culture 2Health News:After Tonsillectomy, Short-Term Antibiotics Effective: Study 2Health News:UC Davis leads attack on deadly new diseases 2Health News:UC Davis leads attack on deadly new diseases 3
... Swing doors, 8 shelves. Over-sized ... doors. Fluorescent interior lighting. Self-Contained System ... foot cord. Full One Year Warranty on ... Warranty on Compressor. Also available as ...
... Independent controls for Digital Thermostat and Digital ... steel. , Interiorwhite anodized aluminum with ... Oversized refrigeration (134A). , Temperature range ... self-closing doors. , Foamed-in-place polyurethane high ...
... The HC Series Large Capacity Refigerators ... embryos, semen, or biological samples at liquid-nitrogen ... holding times and capacities are available to ... Two low profile HCL models are also ...
... refrigerators from Taylor-Wharton are uniquely designed to ... box-type storage racks and the lower operating ... The RackSystems are available in four convenient ... 750 x 2ml vials to 4800 x ...
Medicine Products: